Exagen Inc Stock Current Valuation
| XGN Stock | USD 1.40 0.01 0.72% |
Valuation analysis of Exagen Inc helps investors to measure Exagen's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 4th of May 2024, Enterprise Value is likely to grow to about 27.9 M, while Enterprise Value Over EBITDA is likely to drop (1.14). Fundamental drivers impacting Exagen's valuation include:
Price Book 1.124 | Enterprise Value 11.5 M | Enterprise Value Ebitda (0.67) | Price Sales 0.4854 | Enterprise Value Revenue 0.2424 |
Undervalued
Today
Please note that Exagen's price fluctuation is very risky at this time. Calculation of the real value of Exagen Inc is based on 3 months time horizon. Increasing Exagen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Exagen Inc is useful when determining the fair value of the Exagen stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Exagen. Since Exagen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Exagen Stock. However, Exagen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.4 | Real 2.66 | Target 6.25 | Hype 1.32 | Naive 1.39 |
The real value of Exagen Stock, also known as its intrinsic value, is the underlying worth of Exagen Inc Company, which is reflected in its stock price. It is based on Exagen's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Exagen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Exagen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Exagen Inc helps investors to forecast how Exagen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Exagen more accurately as focusing exclusively on Exagen's fundamentals will not take into account other important factors: Exagen Inc Company Current Valuation Analysis
Exagen's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Exagen Current Valuation | 11.46 M |
Most of Exagen's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Exagen Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Exagen Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Exagen is extremely important. It helps to project a fair market value of Exagen Stock properly, considering its historical fundamentals such as Current Valuation. Since Exagen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Exagen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Exagen's interrelated accounts and indicators.
Click cells to compare fundamentals
Exagen Current Valuation Historical Pattern
Today, most investors in Exagen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Exagen's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Exagen current valuation as a starting point in their analysis.
Exagen Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Exagen Inc has a Current Valuation of 11.46 M. This is 99.92% lower than that of the Biotechnology sector and 99.85% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.93% higher than that of the company.
Exagen Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Exagen's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Exagen could also be used in its relative valuation, which is a method of valuing Exagen by comparing valuation metrics of similar companies.Exagen is currently under evaluation in current valuation category among related companies.
Exagen Fundamentals
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (0.37) % | ||||
| Current Valuation | 11.46 M | ||||
| Shares Outstanding | 17.24 M | ||||
| Shares Owned By Insiders | 30.21 % | ||||
| Shares Owned By Institutions | 58.87 % | ||||
| Number Of Shares Shorted | 11.91 K | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 0.49 X | ||||
| Revenue | 52.55 M | ||||
| Gross Profit | 21.35 M | ||||
| EBITDA | (20.67 M) | ||||
| Net Income | (23.69 M) | ||||
| Cash And Equivalents | 76.39 M | ||||
| Cash Per Share | 4.70 X | ||||
| Total Debt | 23.72 M | ||||
| Debt To Equity | 0.55 % | ||||
| Current Ratio | 9.30 X | ||||
| Book Value Per Share | 1.33 X | ||||
| Cash Flow From Operations | (14.46 M) | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 174 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 24.04 M | ||||
| Total Asset | 56.94 M | ||||
| Retained Earnings | (279.22 M) | ||||
| Working Capital | 35.94 M | ||||
| Net Asset | 56.94 M |
About Exagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Exagen Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Exagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Exagen Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:Check out Exagen Piotroski F Score and Exagen Altman Z Score analysis. Note that the Exagen Inc information on this page should be used as a complementary analysis to other Exagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Exagen Stock analysis
When running Exagen's price analysis, check to measure Exagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exagen is operating at the current time. Most of Exagen's value examination focuses on studying past and present price action to predict the probability of Exagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exagen's price. Additionally, you may evaluate how the addition of Exagen to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Exagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Revenue Per Share 2.972 | Quarterly Revenue Growth 0.072 | Return On Assets (0.20) | Return On Equity (0.73) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.